Pemphigus controlled by dapsone

Area of Science:

• Dermatology
• Immunology
• Autoimmune Blistering Diseases

Background:

• Pemphigus is a group of autoimmune diseases characterized by blistering of the skin and mucous membranes.
• The pathogenesis involves autoantibodies targeting intercellular adhesion molecules in the epidermis.
• Dapsone is a medication used to treat various inflammatory and autoimmune conditions.

Observation:

• Three patients with uncomplicated pemphigus demonstrated clinical improvement with dapsone treatment.
• A decrease in circulating intercellular antibody titers correlated with clinical improvement.
• Immunofluorescence studies revealed distinct antibody binding patterns in pemphigus foliaceus sera.

Findings:

• Dapsone therapy effectively managed pemphigus, indicated by clinical control and reduced autoantibody levels.
• Intercellular antibodies in pemphigus sera exhibit different anatomical binding sites depending on the disease subtype.
• Pemphigus foliaceus sera showed intercellular antibodies localized to the Malpighian and basal cell layers (fluorescent technique) and granular layer (peroxidase technique).

Implications:

• These findings suggest that while the intercellular antibodies in pemphigus vulgaris and pemphigus foliaceus may be similar, they target different specific locations within the epidermis.
• Understanding these distinct binding sites could refine diagnostic approaches and inform targeted therapeutic strategies for pemphigus subtypes.
• Dapsone's efficacy in controlling pemphigus highlights the role of intercellular antibodies in disease activity and response to treatment.